Quarterly ResultMay 6, 2026, 07:07 AM
X4 Pharmaceuticals Q1 Net Loss $(20.2)M; Total Revenue Down 90.6%
AI Summary
X4 Pharmaceuticals reported a net loss of $(20.2) million for Q1 2026, a significant decline from a net income of $0.3 million in Q1 2025. Total revenue decreased by 90.6% to $2.7 million, primarily due to a large license payment in the prior year, though product revenue increased. The company continues its Phase 3 clinical trial for mavorixafor in chronic neutropenia and maintains sufficient liquidity for the next 12 months.
Key Highlights
- Q1 2026 net loss was $(20.2) million, compared to $0.3 million net income in Q1 2025.
- Total revenue decreased 90.6% to $2.7 million from $28.8 million year-over-year.
- Product revenue increased 162.1% to $2.5 million from $0.9 million year-over-year.
- Net cash used in operating activities rose to $(19.6) million from $(12.4) million.
- Cash, cash equivalents, and marketable securities were $233.7 million as of March 31, 2026.
- Weighted average shares outstanding increased to 126.3 million from 6.8 million.
- Full enrollment for the 4WARD trial in CN expected by end of Q3 2026.
- Strategic restructuring in 2025 reduced employee headcount by 65%.